[Experimental and clinical study on the treatment of ischemic skin flap with topical application of PGE1].
OBJECTIVE
To evaluate the efficiency of PGE(1) in relieving the circulatory disorder of ischemic skin flap.


METHODS
New Zealand rabbits were employed in the study with skip flaps each with the size of 2.5 x 6.0 cm(2) being raised from the back. PGE(1) cream in different concentrations, i.e. 0.2%, 0.4%, 0.8% was respectively topically applied to the skin flaps forming 3 groups (n = 10 in each group), while pure cream without PGE(1) was applied to those in control group (n = 30). The PGE(1) was applied 1 hour after the flap was opened, raised and sutured back. Blood perfusion in the flap was measured with Laser Doppler flowmetry before and 5, 10, 15, 20, 30, 45 and 60 mins after PGE(1) application. The tissue samples from the skin flap were harvested at 2 hours after PGE(1) application for immunohistological staining, and the cross sectional area of capillary lumens was measured under microscope. The survival area of the flap was assessed on the 3(rd) day after operation for the calculation of relative survival length of the flap. Clinically, PGE(1) ointment was applied onto the skin flap vulnerable to necrosis, and the outcome of the flap was observed thereafter.


RESULTS
The blood perfusion in animal skin flaps was increased evidently after PGE(1) application, especially at 30 mins after PGE(1) usage when compared with that in control group (P < 0.05). The capillaries in the skin flap in PGE(1) application groups were dilated obviously after drug usage as observed under microscope (P < 0.05). The survival area and relative survival length in groups 1 and 2 on the 3(rd) post-operational day were much more increased when compared with those in other groups (P < 0.01). Clinically, the skin flaps treated with PGE(1) survived well even in the distal end of the flaps.


CONCLUSIONS
The blood perfusion and the survival rate of the skin flaps could be improved by local application of PGE(1) in concentrations of 0.2% or 0.4%.
Li
Chi
C
Department of Burns, Beijing Jishuitan Hospital, Beijing 100035, P. R. China.
Yu
Dong-Ning
DN
Wang
Hao
H
Ma
Chun-Xu
CX
Chen
Hui
H
Sun
Yong-Hua
YH
D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage*; D000818:Animals; D005260:Female; D006801:Humans; D007511:Ischemia / Q000188:drug therapy*; D008297:Male; D011817:Rabbits; D013524:Surgical Flaps / Q000098:blood supply*
D000527:Alprostadil